Predictors of efficacy of allergen immunotherapy in children with seasonal allergic rhinoconjunctivitis and pollen-food allergy syndrom

  • Authors: Makarova SG1,2, Namazova-Baranova LS1,2, Ereshko OA1,3, Vishneva EA1, Kogevnikova OV1, Snovskaya MA1, Alekseeva AA1, Efendieva KE1, Levina YG1
  • Affiliations:
    1. «National Medical Research Center of Children Health» of the Ministry of Health of the Russian Federation
    2. Pirogov Russian National Research Medical University
    3. I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
  • Issue: Vol 15, No 3 (2018)
  • Pages: 43-52
  • Section: Articles
  • URL: https://rusalljournal.ru/raj/article/view/150
  • DOI: https://doi.org/10.36691/RJA150
  • Cite item
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract


Objective of the research. To study predictors of efficacy of AIT in relation to the symptoms of seasonal ARC and PFAS in children with different IgE profiles. Materials and methods. Open prospective observational study of 161 patients aged 5 to 17 years with clinical symptoms of ARC (the annual escalation in April-May, duration of the disease is not less than 2 years, the need for symptomatic therapy in the flowering season of cause-significant plants) and PFAS for products of plant origin. The examination included skin testing, as well as sIgE determination of birch pollen allergen extract, cross-food allergens of plant origin (apple, pear, cherry, peach, carrot) and recombinant birch pollen allergens allergens (rBet v 1, rBet v 2, rBet v 4, rBet v 6) on the automatic analyzer ImmunoCAP250. All patients received two courses of AIT, sublingual administration. Assessment of efficacy was performed using the modified scheme A.D. Ado and diagnostic introduction earlier unbearable product. Conclusion. Monosensitization to rBet v 1 is a clinical and laboratory marker of the high efficacy of AIT in children with seasonal ARC and PFAS. Conclusion. Monosensitization to rBet v 1 is a clinical and laboratory marker of the high efficacy of ACIT in children with pollinosis and cross-PAS. Daily high-dose immunotherapy with standardized extract of birch pollen allergen has a good therapeutic effect, including in relation to the manifestations ofPFAS.

Restricted Access

S G Makarova

«National Medical Research Center of Children Health» of the Ministry of Health of the Russian Federation; Pirogov Russian National Research Medical University

L S Namazova-Baranova

«National Medical Research Center of Children Health» of the Ministry of Health of the Russian Federation; Pirogov Russian National Research Medical University

O A Ereshko

«National Medical Research Center of Children Health» of the Ministry of Health of the Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: ksenya2005@inbox.ru

E A Vishneva

«National Medical Research Center of Children Health» of the Ministry of Health of the Russian Federation

O V Kogevnikova

«National Medical Research Center of Children Health» of the Ministry of Health of the Russian Federation

M A Snovskaya

«National Medical Research Center of Children Health» of the Ministry of Health of the Russian Federation

A A Alekseeva

«National Medical Research Center of Children Health» of the Ministry of Health of the Russian Federation

K E Efendieva

«National Medical Research Center of Children Health» of the Ministry of Health of the Russian Federation

Y G Levina

«National Medical Research Center of Children Health» of the Ministry of Health of the Russian Federation

  1. Global atlas of allergy. Editors: Cezmi A. Akdis, loana Agache. Published by the European Academy of Allergy and Clinical Immunology. 2014: 388.
  2. Worm M., Jappe U., Kleine-Tebbe J., Schafer C., Reese I., Saloga J. et al. Food allergies resulting from immunological cross-reactivity with inhalant allergens. Allergo J. 2014; 23: 1-16.
  3. Адо А.Д. Общая аллергология: Руководство для врачей. 2-е изд. М.: Медицина. 1978: 464.
  4. Семенова ИВ, Выхристенко Л.Р. Комплексная оценка клинической эффективности аллерген-специфической иммунотерапии при пыльцевой аллергии. Вестник ВГМУ. 2014; 13(1): 91-97
  5. Балаболкин И.И. Актуальные проблемы аллергологии детского возраста на современном этапе. Педиатрия. 2012; (3): 69-75
  6. Ant K., Pearce N., Anderson HR, Ellwood P., Montefort S., Shah J. Global map of the prevalence of symptoms of rhinoconjunctivitis in children. The International Study of Asthma and Allergies in Childhood ISAAC Phase Three. Allergy. 2009; 64: 123-148.
  7. Намазова-Баранова Л.С. Аллергия у детей: от теории к практике. М.: Союз педиатров России. 2010-2011: 668.
  8. Вишнева ЕА, Намазова-Баранова ЛС, Алексеева АА, Эфендиева КЕ, Левина ЮГ, Томилова АЮ и соавт. Аллерген-специфическая иммунотерапия у детей с ринитом и риноконъюнктивитом - стандартизация подходов к оценке эффективности. Педиатрическая фармакология. 2015; (2): 173-179
  9. Bousquet J., Khaltaev N., Cruz AA, Denburg J., Fokkens WJ, Togias A. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008; 63: 8-160.
  10. Werfel T, Asero R, Ballmer-Weber BK, Beyer K, Enrique E, Knulst AC et al. Position paper of the EAACI: food allergy due to immunological cross-reactions with commoninhalant allergens. Allergy. 2015; 70: 1079-1090.
  11. Canonica GW, Ansotegui IJ, Pawankar R, Schmid-Grendelmeier P, van Hage M, Baena-Cagnani CE et al. A WAO-ARIA-GA2LEN consensus document on molecularbasedallergy diagnostics. World Allergy Organ J. 2013; 6: 17.
  12. Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R, Hilger C, Hofmaier S et al. EAACI Molecular Allergology User' s Guide. 2016; 27 Suppl 23: 1-250. DOI: 10.1111/ pai.12563.

Views

Abstract - 35

PDF (Russian) - 0

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2018 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies